Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan E Dowell

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancerArkadiusz Z Dudek, Timothy Larson, Michael J McCleod, et al.
Cancer|June 3, 2015
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancerKaren L Reckamp, Marianna Koczywas, Mihaela C Cristea, et al.
International Journal of Radiation Oncology, Biology, Physics|August 15, 2024
Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief ReportYuanyuan Zhang, Puneeth Iyengar, Steven Montalvo, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2015
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancerDavid E Gerber, David A Boothman, Farjana J Fattah, et al.
Translational Lung Cancer Research|December 10, 2025
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancerMary E Gwin, Mitchell S von Itzstein, Jialiang Liu, et al.
Eclinicalmedicine|October 7, 2025
Osimertinib plus consolidative radiotherapy for advanced <i>EGFR</i> mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trialSagus Sampath, Sawsan Rashdan, Puneeth Iyengar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871Lionel D Lewis, Antonius A Miller, Gary L Rosner, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2025
Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical TrialYuanyuan Zhang, Aaron M Laine, Puneeth Iyengar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung CancerMitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Frontiers in Immunology|May 1, 2024
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practiceMitchell S von Itzstein, Yuqiu Yang, Yiqing Wang, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancerArkadiusz Z Dudek, Timothy Larson, Michael J McCleod, et al.
Cancer|June 3, 2015
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancerKaren L Reckamp, Marianna Koczywas, Mihaela C Cristea, et al.
International Journal of Radiation Oncology, Biology, Physics|August 15, 2024
Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief ReportYuanyuan Zhang, Puneeth Iyengar, Steven Montalvo, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2015
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancerDavid E Gerber, David A Boothman, Farjana J Fattah, et al.
Translational Lung Cancer Research|December 10, 2025
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancerMary E Gwin, Mitchell S von Itzstein, Jialiang Liu, et al.
Eclinicalmedicine|October 7, 2025
Osimertinib plus consolidative radiotherapy for advanced <i>EGFR</i> mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trialSagus Sampath, Sawsan Rashdan, Puneeth Iyengar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871Lionel D Lewis, Antonius A Miller, Gary L Rosner, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2025
Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical TrialYuanyuan Zhang, Aaron M Laine, Puneeth Iyengar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung CancerMitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Frontiers in Immunology|May 1, 2024
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practiceMitchell S von Itzstein, Yuqiu Yang, Yiqing Wang, et al.
Pageof 6